BPC-157 vs TB-500
An evidence-first, side-by-side comparison. We compare what the research supports — not marketing claims.
Last updated
Evidence grade
Animal
Animal
What that means
Preclinical evidence from animal models only — not yet shown in humans.
Preclinical evidence from animal models only — not yet shown in humans.
Status
Research compound
Research compound
Mechanism
A stable 15–amino-acid sequence pulled from a protein found in human gastric juice. In rodents it seems to speed healing by recruiting new blood vessels and driving soft-tissue repair, and by keeping tendon and gut cells alive and migrating where they are needed. Exactly how it pulls this off is still being worked out — and none of it has been confirmed in humans.
Marketed as a synthetic form of thymosin β-4 (Tβ4), a peptide the body makes that binds and regulates actin — one of the core building blocks of the cell skeleton. Shift actin dynamics and you influence how cells migrate, how new vessels form, and how inflammation settles at an injury, at least in animal models. One wrinkle the labels rarely mention: much of what is sold as "TB-500" is actually a shorter fragment of Tβ4, not the full molecule used in clinical research. We cover that fragment separately.
Goals
Tendon & ligament repair, Gut healing, Muscle recovery
Tendon & ligament repair, Muscle recovery
Key risks
- No published human RCTs — efficacy in people is unproven
- No long-term human safety data; effects of chronic dosing are unknown
- Sold "for research use only," so purity, dose accuracy, and contamination vary by source
- Consumer "TB-500" is often a fragment, not the clinically studied full peptide
- No completed human RCTs demonstrating the benefits people seek for injuries
- Pro-angiogenic activity is a theoretical concern in people with cancer
Regulatory
Sold "for research use only" — not approved for human consumption.
Sold "for research use only" — not approved for human consumption.